Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Toripalimab+Chemotherapy

Phase 2Small molecule

SSun Yat-sen University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stage IB-IIIA NSCLCRecruiting

Stage IB-IIIA NSCLCPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Stage IB-IIIA NSCLC

NCT06426511

Clinical

Trials by Indication[1]

Stage IB-IIIA NSCLC1 trial

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Recruiting·SSun Yat-sen University·Phase 2·NCT06426511·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Toripalimab+Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab+Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toripalimab+Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Related News